<DOC>
	<DOCNO>NCT02993250</DOCNO>
	<brief_summary>The main purpose study evaluate safety tolerability combination treatment AL-335 , odalasvir ( ODV ) , simeprevir ( SMV ) 8 week Japanese participant genotype 1 2 chronic hepatitis C virus ( HCV ) infection without compensated cirrhosis direct-acting antiviral ( DAA ) naive .</brief_summary>
	<brief_title>A Study Investigate Safety , Pharmacokinetics , Efficacy Combination Treatment AL-335 , Odalasvir , Simeprevir Japanese Participants With Chronic Hepatitis C Genotype 1 2 Virus Infection , With Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Chronic hepatitis C virus ( HCV ) infection All participant must HCV genotype 1 2 infection , determine screen HCV ribonucleic acid ( RNA ) plasma level great equal ( &gt; = ) 10,000 international unit per Milliliter ( IU/mL ) , determine screen Directacting antiviral ( DAA ) naive participant , define receive treatment approve investigational DAA drug chronic HCV infection ; prior HCV therapy consist interferon ( IFN , pegylated nonpegylated ) without ribavirin ( RBV ) allow Participants without cirrhosis compensate cirrhosis Infection HCV genotype 3 , 4 , 5 , 6 Coinfection human immunodeficiency virus ( HIV 1 HIV 2 antibody positive ) hepatitis B virus ( HBV ) ( hepatitis B surface antigen [ HBsAg ] positive ) Prior treatment investigational approve HCV DAA , either combination PegIFN IFN free Any evidence liver disease nonHCV etiology . This include , limited , acute hepatitis A infection ( immunoglobulin M ) , drug alcohol relate liver disease , autoimmune hepatitis , hemochromatosis , Wilson 's disease , alpha 1 antitrypsin deficiency , primary biliary cirrhosis , nonHCV liver disease consider clinically significant investigator Evidence hepatic decompensation assess ChildPugh Class B C follow : history current clinical evidence ascites , bleed varix , hepatic encephalopathy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>